AstraZeneca report finds PreciseInhale ‘reduces the risk’ of failure when developing inhaled drugs

New research released by Astra Zeneca at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27 shows that PreciseInhale can reduce risk and speed up drug development: “dose levels could be selected with confidence before moving into the toxicology study, reducing the risk…inherent with this class of drugs.”

The report found that Inhalation Sciences’ labtech system PreciseInhale delivered results that make it safer and quicker for scientists to choose which candidate drugs to continue developing: “Using this data, dose levels could be selected with confidence before moving into the toxicology study, reducing the risk for tolerability limitations inherent with this class of drugs.”

The report concluded: “it was demonstrated that the PreciseInhale was precise enough to perform this investigation and offers a unique possibility in further exploring inhaled dosing… removing some of the possible variance in other exposure systems.”

The findings are in a poster titled ‘Inhaled Particle Size evaluation on PK Profile using the PreciseInhale’, released at the Association of Inhalation Toxicologists (AIT) Conference in Copenhagen, Denmark, October 26-27.

ISAB’s CSO Per Gerde, inventor of PreciseInhale: “We’re proud Astra Zeneca achieved such positive results. This is clear evidence that the precision and consistency of the data PreciseInhale delivers can save time and reduce costs and risks for the pharma industry when developing drugs to be inhaled.”

For more information about Inhalation Sciences please contact: Fredrik Sjövall, CEO  Email: fredrik.sjovall@inhalation.se Phone: +46 (0)70 64 508 75